GlaxoSmithKline has announced that the Relovair fluticasone furoate/vilanterol trifenatate DPI it is developing with Theravance showed good results in a Phase II study involving 60 COPD patients. Studies of the component drugs for asthma also demonstrated efficacy and safety, according to GSK. Phase III studies for both COPD and asthma are underway. Read the company’s press release.
Positive Phase II results for Relovair dry powder inhaler
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
